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Abstract
Background: The management of Candida infections faces many problems, such as a limited number of antifungal
drugs, toxicity, resistance of Candida to commonly antifungal drugs, relapse of Candida infections, and the high
cost of antifungal drugs. Though azole antifungal agents and derivatives continue to dominate as drugs of choice
against Candida infections, there are many available data referring to the anticandidal activity of essential oils. Since
we have previous observed a good antimicrobial activity of some essential oils against filamentous fungi, the aim of
this study was to extend the research to evaluate the activity of the same oils on Candida albicans, C.glabrata and
C.tropicalis clinical strains, as well as the effects of related components. Essential oils selection was based both on
ethnomedicinal use and on proved antibacterial and/or antifungal activity of some of these oils. Fluconazole and
voriconazole were used as reference drugs.
Methods: The minimum inhibitory concentration (MIC) and the minimal fungicidal concentration (MFC) of essential
oils (thyme red, fennel, clove, pine, sage, lemon balm, and lavender) and their major components were investigated
by the broth microdilution method (BM) and the vapour contact assay (VC).
Results: Using BM, pine oil showed the best activity against all strains tested, though C.albicans was more
susceptible than C.glabrata and C.tropicalis (MIC50-MIC90 = 0.06 %, v/v). On the contrary, sage oil displayed a weak
activity (MIC50-MIC90 = 1 %, v/v). Thyme red oil (MIC50-MIC90 ≤ 0.0038 %, v/v for C.albicans and C.tropicalis, and 0.
0078- < 0.015 %, v/v for C.glabrata), followed by lemon balm, lavender and sage were the most effective by VC.
Carvacrol and thymol showed the highest activity, whereas linalyl acetate showed the lowest activity both by two
methods. α-pinene displayed a better activity by BM than VC.
Conclusion: Results show a good activity of essential oils, mainly thymus red and pine oils, and their components
carvacrol, thymol and α-pinene against Candida spp., including fluconazole/voriconazole resistant strains. These data
encourage adequately controlled and randomized clinical investigations. The use in vapour phase could have
additional advantages without requiring direct contact, resulting in easy of environmental application such as in
hospital, and/or in school.
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Background
Candidiasis is the most common opportunistic yeast in-
fection and encompasses infections that range from
superficial mucosal infections, such as oral thrush and
vaginitis, to systemic and potentially life-threatening dis-
eases, such as disseminated candidiasis. In the last two
decades, it has been observed a considerable increase in
the incidence of deep fungal infections, not only in im-
munocompromised patients related to nosocomial infec-
tions, but also in healthy subjects. Moreover, the
incidence of C. albicans, the leading pathogenic Candida
species so far, has declined while that of non-albicans
Candida is increased [1].
The most commonly used classes of antifungal agents
to treat Candida infections are the azoles, polyenes, and
echinocandins; however, the management of Candida
infections faces many problems, such as toxicity, resist-
ance of Candida to commonly used antifungal drugs,
relapse of Candida infections, and the high cost of anti-
fungal drugs [2, 3]. To elude these problems, investiga-
tors are exploiting alternative therapeutic strategies,
such as the use of natural products, especially essential
oils (EOs) [4–7].
EOs have long been used in ethnomedicine as effective
and safe antifungal agents; however, good scientific and
clinical data that either supports or contravenes the ef-
fectiveness of these alternative therapies are still needed
before consumers can be sure they will enjoy any bene-
fits. Previously we have studied the antimicrobial activity
of thyme red, clove, pine, sage, lemon balm, fennel, lav-
ender EOs against filamentous fungi [8]. Hence, the ob-
jective of this study was to extend the research to
evaluate the activity of the same EOs on Candida albi-
cans and non-albicans Candida strains, as well as the
effects of related EO components, by using two investi-
gative tools, such as the broth microdilution method
(BM) and the vapour contact assay (VC). EOs selection
was based both on ethnomedicinal use and on proved
antibacterial and/or antifungal activity of some of these
oils [8, 9]. Fluconazole and voriconazole were used as
reference drugs to compare EOs activity.
Methods
Essential oils and their components
The EOs have directly been purchased from Azienda
Agricola Aboca (Sansepolcro, Arezzo) as steam distilled
samples obtained from Thymus vulgaris L. (thyme red),
Foeniculum vulgare Mill. var. dulce DC (fennel), Eugenia
caryophyllata Thumb. (clove), Pinus sylvestris L. (pine),
Salvia officinalis L. (sage), Melissa officinalis L. (lemon
balm) and Lavandula vera DC (lavender). The compo-
nents carvacrol, eugenol, linalool, linalyl acetate, thymol
and α-pinene (≥98 % purity) were supplied by Sigma
Aldrich (Steinheim, Germany) and used as received
without any further purification. EOs and related com-
ponents were storage at 4 °C until use.
Essential oils and their components stock solutions
Stock solutions of each EO and its components were
prepared in ethanol (1:25) and diluted (1:20) to obtain a
final concentration of 2 % (v/v) in RPMI-1640 without
sodium bicarbonate and with L-glutamine (Invitrogen,
San Giuliano Milanese, Milano, Italy), buffered to pH 7.0
with 0.165 M morpholinepropanesulfonic acid (MOPS)
(Sigma) at a concentration of 0.165 mol 1−1 and supple-
mented with glucose 18 g/L. To enhance EOs solubility,
Tween-80 (Sigma-Aldrich) was included at a final con-
centration of 0.001 % (v/v).
Antifungal drugs
Fluconazole and voriconazole powders (≥98 % purity by
HPLC) were purchased from Sigma-Aldrich (n° F8929
and PZ0005, respectively). Fluconazole stock solutions
were prepared in sterile distilled water, while voricona-
zole in 100 % dimethyl sulfoxide (Sigma-Aldrich), and
stored at −20 °C until use.
Yeasts
Forty-six yeasts, including C. albicans (n = 26), C. glab-
rata (n = 10) and C. tropicalis (n = 10) were collected
from various specimens (blood, normally sterile body
fluids, deep tissue, genital tract, gastrointestinal tract, re-
spiratory tract) from hospitalized patients in Turin (Italy).
The strains were identified by standard methods (corn-
meal for blastoconidia, germ-tube formation, pseudohy-
phae and true hyphae, and growth on CHROMagar™
Candida (BD, Milan, Italy) and with commercially avail-
able yeast identification system (API ID32C panels, bio-
Mérieux, Rome, Italy) [10].
Inoculum preparation
Yeasts inocula were prepared by picking two to three
colonies of >1 mm diameter from an overnight culture
of Candida spp. on Sabouraud dextrose (SAB) agar at
35 °C, and suspending them in 2 mL of 0.85 % normal
saline, to yield a yeast stock suspension of ≈ 5 × 106
cells/mL by 0.5 McFarland standard. A working suspen-
sion was made by a 1:100 dilution followed by a 1:20 di-
lution of the stock suspension with RPMI 1640 broth
medium (0.2 % glucose) (Sigma, Milan, Italy), which re-
sulted in ≈ 2.5 × 103 cells/mL, confirmed by colony counts
in triplicate. The cell density was adjusted to 2.0 × 103
cells/mL, confirmed by colony counts in triplicate.
In vitro antimicrobial assays
Broth microdilution method
The antimicrobial activity of EOs and their components
was determined using a BM susceptibility assay,
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according to CLSI document M27-A3 for yeasts with
some modifications [11]. Minimum inhibitory concen-
tration (MIC) determination was performed by serial di-
lution using 96-well microtitre plates (Sarstedt, Milan,
Italy). Doubling dilutions of the EOs ranging from 2 to
0.0038 % (v/v) were prepared in 96-well microtitre trays
in RPMI-1640 with MOPS buffered to pH 7. Further-
more, each yeast strain included in the study was tested
for its sensitivity to fluconazole and voriconazole follow-
ing the M27-A3 protocol [11]. Doubling dilutions of the
two reference antifungal compounds, ranging from 128
to 0.008 μg/mL, were prepared in 96-well microtitre
trays in RPMI-1640 with MOPS buffered to pH 7. After
inoculum addition (0.1 mL), the trays were incubated
under normal atmospheric conditions at 37 °C for 48 h.
A sterile medium incubated under the same condition
was used as a blank, while the medium inoculated with
the target microorganisms (without the oil/drug) was
used as a positive control of growth. All determinations
were performed in triplicate.
The lowest concentration of the oil showing complete
inhibition of visible growth was defined as MIC. The ab-
sence of visible growth was determined under a binocu-
lar microscope. MICs of azoles were read as the lowest
drug concentration that produced ≥50 % growth inhib-
ition in comparison with growth control. The CLSI re-
sistance breakpoint for fluconazole was defined as a
MIC of ≥ 2 μg/mL against C. albicans, C. tropicalis and
a MIC of ≥32 μg/mL against C. glabrata; the CLSI re-
sistance breakpoint for voriconazole was defined as a
MIC of ≥ 0.5 μg/mL against C. albicans and C. tropica-
lis. CLSI has not assigned breakpoints for voriconazole
and C. glabrata, and recommended the epidemio-
logical cut-off value (ECV) of 0.5 μg/mL to be used to
differentiate wild type (WT) from non-WT strains of
this species [12].
The minimal fungicidal concentration (MFC) of EOs,
their components, and drugs was determined by subcul-
turing 10 μL of broth taken from all the wells without
visible growth onto SAB agar plates that do not contain
the test agents. After incubation for 48 h at 37 °C, MFC
was defined as the lowest concentration of oil/drug
resulting in the death of 99.9 % of the inoculum in no
growth on subculture [8, 13].
Vapour contact assay
The effect of volatile oil fraction was studied with invert
Petri dishes method as previously reported [8, 14].
Double-strength concentrated RPMI 1640 with MOPS,
adjusted to pH 7.0 was mixed with molten 3.0 % (w/v)
agar in an equal ratio immediately before the assay. The
RPMI agar was poured into a 90 mm Petri dish and spot
inoculated with 100 μL of standardized suspension of
each strain tested. A glass slide (1-cm size) was placed in
the cover of each Petri dish, so that it did not directly
touch the surface of the agar medium, and various
amounts of pure EOs or their components were added to
obtain final concentration ranging from 1 to 0.0019 %, v/v
air space. The space inside of the sealed Petri dish was cal-
culated to be 70 cm3 air. The plates were sealed with vinyl
tape immediately after inoculation, and incubated at 37 °C
for 48 h. The control, consisting of RPMI medium with
MOPS, was included. The MIC (percentage, v/v air space)
was determined by comparison with the control and was
defined as the lowest concentration of EO inhibiting the
visible growth.
Data analysis
The data from at least three replicates were evaluated
and modal results were calculated.
Results and discussion
The research on EOs and closely related components
has been recently intensified, due to their biological,
antioxidant and antimicrobial properties [5, 15–18].
Moreover, there is a growing evidence that EOs in
vapour phase are effective antimicrobial systems and
that they could have advantages over the use of EOs in
liquid phase, especially in a hospital environment. In
fact, our previously studies demonstrated a better activ-
ity in vapour phase of some oils (thyme red, fennel,
clove, pine, sage, lemon balm and lavender) against hu-
man and plant pathogen filamentous fungi [8].
In this study, we evaluated by two methods (BM and
VC) the antifungal activity of seven EOs including thyme
red, fennel, clove, pine, sage, lemon balm and lavender
(Table 1) and some their components (Table 2), towards
46 clinical isolates of C. albicans, C. glabrata and C. tro-
picalis. In literature, there are some available data refer-
ring to the anticandidal activity of EOs such as thyme,
clove, pine, fennel, sage, and lemon balm [5–7, 19, 20].
Our results, reported as concentrations of EO, major
components, fluconazole and voriconazole, are showed
as MIC50 (Minimum Inhibitory Concentration required
to inhibit the growth of 50 % of yeasts) and MIC90
(Minimum Inhibitory Concentration which inhibits the
growth of 90 % of yeasts), respectively (Tables 1, 2).
As regard BM, thyme red and pine EOs showed the
best activity against all strains tested, though C.albicans
proved to be more susceptible than C.glabrata and
C.tropicalis to pine oil (MIC50 - MIC90 = 0.06 %, v/v).
On the contrary, fennel, clove, sage and lavender EOs
showed the highest MICs (Table 1), whereas lemon balm
oil displayed a weak activity against both C.tropicalis
(MIC50 - MIC90 = 0.25 %, v/v) and C. glabrata (MIC50 -
MIC90 = 0.125–1 %, v/v, respectively).
Interestingly, the MIC values obtained with VC were
lower than those in liquid medium for all the EOs tested,
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except for pine. Specifically, thyme red was the oil with
the highest activity (MIC90 < 0.0038 %, v/v) against
C.albicans, followed by lemon balm, lavender, and sage
(Table 1).
The different antifungal activity in liquid and vapour
phase could be due to the characteristics of EOs such as
high hydrophobicity and volatility. In fact, when added
to a medium, the EO distributes more or less into the
aqueous phase depending on its relative hydrophobicity.
In the liquid phase, the activity depends upon the diffu-
sibility and solubility of the EOs in the medium while in
the vapour assay it depends upon the volatility [2].
MIC values showed that EOs activity is higher than
that obtained with the conventional antifungal drugs
tested against C. glabrata e C. tropicalis, both resistant
to fluconazole and voriconazole (fluconazole MIC90 = 64
and 16 μg/mL, respectively and voriconazole MIC90 = 4
and 2 μg/mL, respectively) (Table 1).
Table 1 Minimum inhibitory concentration (MIC) of EOs (%, v/v) and drugs (μg/mL) against Candida spp. evaluated by the broth
microdilution (BM) and vapour contact (VC) methods
Essential oils/drugs Methods C.albicans (n = 26) C.glabrata (n = 10) C.tropicalis (n = 10)
Range MIC 50 MIC 90 range MIC 50 MIC 90 range MIC 50 MIC 90
Thyme red BM 0.03–0.25 0.03 0.125 0.06–0.25 0.06 0.125 0.06–0.25 0.06 0.25
VC <0.0038 <0.0038 <0.0038 <0.0019–0.03 0.0078 0.015 0.0075–0.015 0.0038 0.0038
Fennel BM 0.25–1 0.25 1 0.25–1 0.25 1 0.5–1 1 1
VC 0.25–1 0.25 0.5 0.25–1 0.25 0.25 0.25–1 0.25 0.5
Clove BM 0.25–1 0.25 1 0.25–1 0.25 1 0.125–1 0.25 1
VC 0.25–1 0.5 0.5 0.25–0.5 0.5 0.5 0.06–1 0.06 0.25
Pine BM 0.03–0.06 0.06 0.06 0.0075–0.5 0.015 0.25 0.015–0.5 0.03 0.5
VC 0.5–1 1 1 0.5–1 1 1 0.5–1 1 1
Sage BM 0.5–1 1 1 0.5–1 1 1 0.5–1 1 1
VC 0.06 0.06 0.06 0.125–0.25 0.125 0.25 0.06 0.06 0.06
Lemon balm BM 0.5–1 1 1 0.5–1 0.125 1 0.06–0.5 0.25 0.25
VC 0.015–0.03 0.015 0.015 0.015–0.06 0.03 0.06 0.0038–0.015 0.015 0.015
Lavender BM 0.5–1 1 1 0.5–1 0.25 1 0.125–1 0.25 1
VC 0.0019–0.06 0.06 0.06 0.0075–0.06 0.03 0.06 0.015–0.06 0.03 0.06
Fluconazole BM 0.5- > 64 0.50 4.00 0.125- > 64 4.00 64.00 0.25- > 64 2.00 16
Voriconazole BM 0.008–8 0.06 0.12 0.008–8 0.25 4.00 0.032–8 0.12 2.00
Results were obtained from 3 independent experiments performed in duplicate and expressed as modal results
Table 2 Minimum inhibitory concentration (MICs) of EOs components (%, v/v) by the broth microdilution (BM) and vapour contact
(VC) methods
Components Methods C.albicans (n = 26) C.glabrata (n = 10) C.tropicalis (n = 10)
Range MIC 50 MIC 90 Range MIC 50 MIC 90 Range MIC 50 MIC 90
Carvacrol BM 0.06–0.5 0.125 0.125 0.06–0.25 0.125 0.25 0.25–0.5 0.25 0.25
VC 0.0038 0.0038 0.0038 <0.0019 <0.0019 <0.0019 <0.0019–0.0038 <0.0019 <0.0019
Eugenol BM 0.25 0.25 0.25 0.125–0.25 0.125 0.25 0.25–0.5 0.25 0.25
VC 0.125–0.5 0.125 0.125 0.06–0.25 0.125 0.125 0.125–0.25 0.125 0.125
Linalool BM 0.125–1 0.25 0.25 0.125–1 0.5 0.25 0.25–0.5 0.25 0.25
VC 0.0075 0.0075 0.0075 0.0075–0.03 0.015 0.03 0.0015–0.03 0.03 0.03
Linalyl acetate BM 1 1 1 1 1 1 1 1 1
VC 1 1 1 1 1 1 1 1 1
Thymol BM 0.06–0.125 0.06 0.06 0.06–0.25 0.125 0.125 0.125–0.5 0.125 0.125
VC 0.0038 0.0038 0.0038 0.0019–0.0038 0.0019 0.0019 <0.0019 <0.0019 <0.0019
α-Pinene BM 0.06–0.125 0.06 0.06 0.06–0.125 0.06 0.125 0.125–0.5 0.125 0.125
VC 0.25–0.5 0.25 0.5 0.25–0.5 0.25 0.5 0.25–1 0.5 0.5
Results were obtained from 3 independent experiments performed in duplicate and expressed as modal results
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The data of the present study can be explained be-
cause of chemical composition of EOs, we had already
reported in a previous study [8]. These EOs contained
the following major components determined by gas
chromatography–mass spectrometry: thymol (26.5 %, v/
v), ρ-cymene (16.2 %, v/v), limonene (13.2 %, v/v), α-
pinene (13.2 %, v/v), carvacrol (7.8 %, v/v) in thyme red;
anethole (72.1 %, v/v), fenchone (14.2 %, v/v) in fennel;
eugenol (77.5 %, v/v), eugenyl acetate (7.6 %, v/v) in
clove; α-pinene (55.7 %, v/v), β-pinene, (10 %, v/v), lim-
onene (9.7 %, v/v) in pine; cis-thujone (29.4 %, v/v),
camphor (22.6 %, v/v), 1,8 cineole (7.7 %, v/v) in sage;
citronellal (29.4 %, v/v), limonene (22.6 %, v/v), geranial
(8.8 %, v/v) in lemon balm; linalool (41.9 %, v/v), linalyl
acetate (32.7 %, v/v) in lavender. The EOs tested in this
study showed the presence of significant amounts of
monoterpenes, mainly represented by thymol, α-pinene,
and linalool compounds, in accordance with previous
published data even if with different percentile [21]
(Table 2). Carvacrol and thymol exerted an interesting
anti-Candida in vitro activity both by BM and VC, similar
to previous findings [22–24], even against fluconazole-
resistant C. glabrata and C. tropicalis strains. α-pinene
showed a better activity by BM than VC; conversely, lina-
lyl acetate showed the lowest activity against all strains
tested both by two methods. Generally, MFCs were one or
more concentrations higher than MICs (Table 3), suggest-
ing a fungicidal activity of the EOs at low concentrations
against yeasts cells, probably due to their related compo-
nents, such as terpenoids and phenolics known for their
broad-spectrum antimicrobial activity [25, 26]. However,
the mechanisms behind the antifungal activity of EOs are
not fully understood.
High antifungal activity of examined EOs, also against
antibiotic-resistant isolates is according to recent evi-
dence of some authors [20, 27, 28]. However, it is diffi-
cult to compare the data with the literature because the
antimicrobial activity of EOs and their components are
influenced by the several factors including chemical
compositions and experimental conditions.
The composition of EOs varies significantly because of
plant different species and chemotypes, geographical ori-
gin, season and extraction procedure [29]. In this con-
text, Tampieri et al. [30] studied a T. vulgaris EO based
on carvacrol (41.33 %), p-cymene (17.53 %) and thymol
(5.34 %) and observed a fungistatic activity of the EO
tested [30]. Conversely, we studied a T. vulgaris EO with
different composition; in fact, thymol was 26.5 %, p-
cymene 16.2 % and carvacrol 7.8 % and we observed a
fungicide activity of the EO tested.
Regarding experimental conditions, it is important to
underline that EOs antimicrobial activity data depend
on the methodology used, the variability of which in-
cludes factors such as inoculum size, medium used,
and use of sealants, surfactants and solvents such as
Tween, dimethylsulphoxide and ethanol. In part, these
may explain the differences in results obtained by dif-
ferent research groups [31].
Results obtained in this study highlight the activity of
the main compounds, thymol in thyme red oil (26.5 %)
and α-pinene in pine oil (55 %). However, some data
suggest that components presented in small amounts in
EOs, such as carvacrol, also could play an important role
in antimicrobial activity due to the possible synergistic
action with other components [24, 25, 32, 33].
Thymol, known to be lipophilic, together with carva-
crol can enter between the fatty acyl chains making up
membrane lipid bilayers, thus altering the fluidity and
permeability of cell membranes [34].
Some authors indicate that this action on fungi, par-
ticularly on C. albicans, affects the regulation and func-
tion of important membrane-bound enzymes that
catalyze the synthesis of a number of major cell wall
polysaccharide components, such as β-glucans, chitin
and mannan, thus disturbing cell growth and envelope
morphogenesis [26].
Our data on thymol are in agreement with those of
Fontenelle et al. [7] who demonstrated its potent anti-
microbial activity against C. albicans with MIC = 39 μg/
mL. On the contrary, our data do not support those of
Zore et al. [35], who reported the considerable activity
Table 3 Minimum fungicidal concentration (MFC) of EOs (%, v/v)









Thyme red 0.06-0.25 0.06-0.25 0.06-0.5
Fennel 0.5- > 1 0.25- > 1 1- > 1
Clove 0.25- > 1 0.25- > 1 0.5- > 1
Pine 0.03-0.125 0.03-0.5 0.06-1
Sage >1 >1 >1
Lemon balm >1 >1 >1
Lavender >1 >1 >1
Carvacrol 0.125-1 0.25-1 0.25-1
Eugenol 0.5 0.25 0.5
Linalool 0.5 0.5 1
Linalyl acetate 1- > 1 1- > 1 1- > 1
Thymol 0.125-0.25 0.25 0.25-0.5
α-Pinene 0.5-1 0.5-1 1
Fluconazole 2 - >64 0.5 - >64 0.5- > 64
Voriconazole 0.06-8 0.12-8 0.12-8
Results were obtained from 3 independent experiments performed in duplicate
and expressed as modal results
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of linalyl acetate against 39/48 yeast isolates with MIC =
0.064 % (v/v), but they are in agreement with D’Auria et
al. against C. albicans (Table 2) [7, 35, 36].
In accordance with our previous findings against clin-
ical filamentous fungi and since active compounds of
EOs are highly volatile, EOs possess high antimicrobial
activity in vapour phase [8].
Phenols, such as thymol and carvacrol, are among the
most active natural antioxidants and antimicrobials
found in EOs [2, 7]. However, due to their poor water
solubility and the requirement for high concentrations
to reach a therapeutic effect, the efficiency of these com-
pounds in treatment is limited. It is important to
emphasize that thymol is a smaller and more volatile
molecule than the ether-containing eugenol from clove.
According to Suhr et al. [29], thyme was also generally
more effective than clove in the volatile experiment
(Table 2) [29].
Conclusions
Data reported in this study show a good activity of EOs,
mainly thymus red and pine oils, against Candida spp.,
including fluconazole/voriconazole resistant strains. This
activity could be related to main components of EOs,
such as carvacrol, thymol, and α-pinene that exerted a
significant antifungal action.
Overall, our experimental data give substantial support
to previous empirical evidence or literature data on the
anticandidal activity of different EOs. These data also en-
courage adequately controlled and randomized clinical in-
vestigations, including different screening methods and
action mechanisms studies for future applications: i.e. a
volatile screening method should be employed for fumiga-
tion or active packaging purposes. The use in vapour
phase could have additional advantages without requiring
direct contact, resulting in simple and convenient environ-
mental application such as in hospital, and/or in school.
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